Cargando…

What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?

Numerous clinical trials investigating neoadjuvant immune checkpoint inhibitors (ICI) have been performed over the last 5 years. As the number of neoadjuvant trials increases, attention must be paid to identifying informative trial endpoints. Complete pathologic response has been shown to be an appr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cameron, Robert B., Hines, Jacobi B., Torri, Valter, Porcu, Luca, Donington, Jessica, Bestvina, Christine M., Vokes, Everett, Dolezal, James M., Esposito, Alessandra, Garassino, Marina C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504845/ https://www.ncbi.nlm.nih.gov/pubmed/37720499 http://dx.doi.org/10.1177/17588359231198446

Ejemplares similares

AB012. Automated histologic subtyping of thymic epithelial tumors with deep learning
por: Dolezal, James M., et al.
Publicado: (2022)

Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer
por: Hines, Jacobi B., et al.
Publicado: (2023)

Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
por: Rulli, Eliana, et al.
Publicado: (2018)

Improved Endpoints for Cancer Immunotherapy Trials
por: Hoos, Axel, et al.
Publicado: (2010)

CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
por: Gutiontov, Stanley I., et al.
Publicado: (2021)

Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials
por: Floriani, Irene, et al.
Publicado: (2008)

Clinical endpoints in allergen immunotherapy: State of the art 2022
por: Gerth van Wijk, Roy, et al.
Publicado: (2023)

What Is the Ideal Instagram Filter?
por: Youn, Anthony
Publicado: (2019)

γδ T Cells: The Ideal Tool for Cancer Immunotherapy
por: Yazdanifar, Mahboubeh, et al.
Publicado: (2020)

Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer
por: Dröge, Leif Hendrik, et al.
Publicado: (2021)

What Should Be Our Ideal in Prosthetics
por: Chappelle, W. F.
Publicado: (1922)

What is the ideal management of Krukenberg syndrome?
por: Arró Ortiz, Carolina, et al.
Publicado: (2022)

Severity of COVID-19 in patients with lung cancer: evidence and challenges
por: Passaro, Antonio, et al.
Publicado: (2021)

Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system
por: Prelaj, Arsela, et al.
Publicado: (2020)

What is the ideal triage process and the resources it requires?
por: Kellett, John
Publicado: (2021)

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
por: Marron, Thomas U, et al.
Publicado: (2022)

Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials
por: George, Thomas J., et al.
Publicado: (2015)

Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy
por: Luen, Stephen L., et al.
Publicado: (2019)

Meeting patient expectations in migraine treatment: what are the key endpoints?
por: Antonaci, Fabio, et al.
Publicado: (2008)

Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy
por: Jia, Yangyang, et al.
Publicado: (2023)

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials
por: Li, Yuanfang, et al.
Publicado: (2023)

A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future
por: Ren, Sijia, et al.
Publicado: (2021)

Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
por: Liu, Hua, et al.
Publicado: (2022)

What is an ‘ideally imperfect’ crystal? Is kinematical theory appropriate?
por: Fewster, Paul F.
Publicado: (2016)

What is the ideal biological marker in diagnosis of diabetic neuropathies?
por: Jin, Heung Yong, et al.
Publicado: (2013)

The ideal marker for measuring GFR: what are we looking for?
por: Claudio, Maioli, et al.
Publicado: (2020)

En Route to Completion: What Is An Ideal Reference Genome?
por: Pan, Weihua, et al.
Publicado: (2022)

Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
por: Garcia, Diogo, et al.
Publicado: (2021)

Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
por: Swarbrick, Alexander, et al.
Publicado: (2013)

Erratum to: Breast reconstruction after neoadjuvant radio chemotherapy: review and personal technique IDEAL concept
por: Nestle-Krämling, Carolin, et al.
Publicado: (2016)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Calcium affects on vascular endpoints
por: Patel, Vaishali B, et al.
Publicado: (2012)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

The Keynesian Endpoint
por: Crescenzi, Tony
Publicado: (2010)

Endpoint security
por: Kadrich, Mark
Publicado: (2007)

Dynamic models of immune responses: what is the ideal level of detail?
por: Thakar, Juilee, et al.
Publicado: (2010)

What Is the Ideal Core Number for Ultrasound-Guided Prostate Biopsy?
por: Chambó, Renato Caretta, et al.
Publicado: (2014)

The Ideal Graduate Study Institution.—What Germany Has Done
Publicado: (1909)

The Ideal Graduate Study Institution.—What Germany Has Done
Publicado: (1909)

The Ideal Graduate Study Institution.—What Germany Has Done
Publicado: (1909)

Cannot write session to /tmp/vufind_sessions/sess_9bcucb5baqp8em0j475hhj8ek8